Table 1 Clinical characteristics of COVID-19 patients.
From: SARS-CoV-2 antigenemia and RNAemia in association with disease severity in patients with COVID-19
Characteristics | Total (N = 119) | Survival group (n = 102) | Fatal group (n = 17) | P value | |||
|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
Male gender | 55 | 46.2% | 49 | 48.0% | 6 | 35.3% | 0.329 |
Age, median (IQR) | 66.0 | 52.0–79.0 | 62.0 | 48.5–74.3 | 83.0 | 79.0–89.0 | < 0.001 |
Antigenemia | 99 | 83.2% | 83 | 81.4% | 16 | 94.1% | 0.001 |
No elevation | 67 | 56.3% | 63 | 61.8% | 4 | 23.5% | |
Elevation | 33 | 27.7% | 22 | 21.6% | 11 | 64.7% | |
Unknown of elevation | 19 | 16.0% | 17 | 16.7% | 2 | 11.8% | |
Antigenemia peak, Mean ± SD | 119 | 463.36 ± 1566.10 | 102 | 342.31 ± 1219.67 | 17 | 1189.65 ± 2836.22 | 0.242 |
Antigenemia peak, median(IQR) | 119 | 26.40 (3.51–148.0) | 102 | 25.75 (1.51–157.0) | 17 | 35.70 (13.05–694.15) | 0.242 |
RNAemia during hospitalization | 28 | 23.5% | 15 | 14.7% | 13 | 16.5% | < 0.001 |
RNAemia on admission | 21 | 17.6% | 10 | 9.8% | 11 | 64.7% | < 0.001 |
Nasopharyngeal viral load on admission, Ct value (mean ± SD) | 119 | 22.58 ± 8.632 | 102 | 23.38 ± 8.876 | 17 | 17.80 ± 4.884 | 0.001 |
Nasopharyngea viral load on admission, Ct value [median(IQR)] | 119 | 21.01 (15.23–29.15) | 102 | 22.22 (15.91–30.71) | 17 | 18.38 (13.79–20.88) | 0.001 |
Comorbidities, N (%) | 77 | 64.7% | 62 | 60.8% | 15 | 88.2% | 0.028 |
Cardiovascular disease | 16 | 13.4% | 14 | 13.7% | 2 | 11.8% | 1.000 |
Diabetes mellitus | 30 | 25.2% | 22 | 21.6% | 8 | 47.1% | 0.035 |
Hypertension | 46 | 38.7% | 36 | 35.3% | 10 | 58.8% | 0.065 |
Chronic lung disease | 3 | 2.5% | 1 | 1.0% | 2 | 11.8% | 0.053 |
Cancer | 8 | 6.7% | 7 | 6.9% | 1 | 5.9% | 1.000 |
Chronic kidney disease | 2 | 1.7% | 2 | 2.0% | 0 | 0.0% | 1.000 |
Severity PSI*, mean ± SD | 66.32 | 24.930 | 62.44 | 23.453 | 92.92 | 17.863 | < 0.001 |
Symptoms | |||||||
Fever | 44 | 37.0% | 38 | 37.3% | 6 | 35.3% | 0.877 |
Cough | 41 | 34.5% | 35 | 34.3% | 6 | 35.3% | 0.937 |
Headache | 9 | 7.6% | 9 | 8.8% | 0 | 0.0% | 0.355 |
Chill | 19 | 16.0% | 19 | 18.6% | 0 | 0.0% | 0.071 |
Sore throat | 18 | 15.1% | 17 | 16.7% | 1 | 5.9% | 0.464 |
Myalgia | 16 | 13.4% | 16 | 15.7% | 0 | 0.0% | 0.123 |
Treatments | |||||||
Oxygen inhalation | 61 | 51.3% | 44 | 43.1% | 17 | 100.0% | < 0.001 |
High flow oxygen therapy | 33 | 27.7% | 17 | 16.7% | 16 | 94.1% | < 0.001 |
Mechanical ventilation | 20 | 16.8% | 7 | 6.9% | 13 | 76.5% | < 0.001 |
Antiviral | 56 | 47.1% | 40 | 39.2% | 16 | 94.1% | < 0.001 |
Steroids | 43 | 36.1% | 28 | 27.5% | 15 | 88.2% | < 0.001 |
